Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
- 1 September 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (25) , 4155-4161
- https://doi.org/10.1200/jco.2008.21.6895
Abstract
Purpose Recent data suggest that the glutamatergic system is important in the proliferation and migration of glioblastoma. Talampanel is a well-tolerated, oral α-amino-3-hydroxy-5-methyl-4-isoxazol...Keywords
This publication has 31 references indexed in Scilit:
- AMPA receptors promote perivascular glioma invasion via β1 integrin–dependent adhesion to the extracellular matrixNeuro-Oncology, 2009
- Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastomaNeuro-Oncology, 2008
- Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: Potential therapeutic application for treatment of gliomasNeuro-Oncology, 2008
- A role for glutamate in growth and invasion of primary brain tumorsJournal of Neurochemistry, 2008
- Autocrine Glutamate Signaling Promotes Glioma Cell InvasionCancer Research, 2007
- Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signalingOncogene, 2007
- Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegenerationPharmacology & Therapeutics, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium studyNeuro-Oncology, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958